Joseph Walter Vazzano Sells 17,795 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano sold 17,795 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $6.76, for a total transaction of $120,294.20. Following the completion of the transaction, the chief financial officer now owns 491,246 shares in the company, valued at approximately $3,320,822.96. The trade was a 3.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Abeona Therapeutics Price Performance

ABEO traded down $0.20 on Monday, hitting $6.54. 1,064,341 shares of the company's stock traded hands, compared to its average volume of 642,523. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a one year low of $3.93 and a one year high of $7.32. The company's 50 day simple moving average is $5.59 and its 200-day simple moving average is $5.58. The firm has a market cap of $334.57 million, a price-to-earnings ratio of -2.43 and a beta of 1.54.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.11. As a group, research analysts anticipate that Abeona Therapeutics Inc will post -1.16 EPS for the current year.

Analysts Set New Price Targets

ABEO has been the topic of several research analyst reports. Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $19.00 target price on the stock. HC Wainwright upped their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Stifel Nicolaus cut their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Abeona Therapeutics has an average rating of "Moderate Buy" and an average target price of $19.25.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics during the fourth quarter valued at approximately $58,000. Squarepoint Ops LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $67,000. Cannon Global Investment Management LLC acquired a new position in shares of Abeona Therapeutics in the first quarter valued at about $67,000. Oxford Asset Management LLP purchased a new position in Abeona Therapeutics during the 4th quarter worth approximately $118,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $190,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.